NRAS mutation

Activating NRAS mutations detected by sequencing or PCR; used as a predictive marker in colorectal cancer (anti-EGFR antibodies) and studied in melanoma.

CI-BIO-00000017NRAS graph →NCIt C41381 Tumor-agnostic · 4 approval rows

Also calledNRAS-mutant · NRAS-mutated

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug in derived setRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Trametinib US FDA · May 29, 2013 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (13)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Colorectal Neoplasm	17	16	1	—	1 / 6 / 8 / 2 / 0
Melanoma	15	12	2	1	0 / 6 / 6 / 3 / 0
Cutaneous Melanoma	9	9	—	—

Derived

Drugs with predictive evidence (20)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
CetuximabMonoclonal Antibody	14	—	14	A	0 / 13	Malignant Colorectal Neoplasm
BinimetinibSmall Molecule	8	8	—	B	7 / 0	Cutaneous Melanoma, Melanoma, Neuroblastoma, Solid Neoplasm
TrametinibSmall Molecule	6	6	—	B	5 / 0	Cutaneous Melanoma, Lung Non-Small Cell Carcinoma, Malignant Neoplasm, Malignant Ovarian Serous Tumor +1
SelumetinibSmall Molecule	6	6	—	B	4 / 0	Cutaneous Melanoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Neoplasm
BelvarafenibSmall Molecule	5	5	—	C	5 / 0	Acral Lentiginous Melanoma, Melanoma, Mucosal Melanoma
Chemotherapy	4	—	4	B	0 / 4	Malignant Colorectal Neoplasm
IrinotecanSmall Molecule	4	—	4	C	0 / 4	Malignant Colorectal Neoplasm
VemurafenibSmall Molecule	3	—	3	B	0 / 3	Cutaneous Melanoma, Melanoma
PanitumumabMonoclonal Antibody	2	—	2	A	0 / 2	Malignant Colorectal Neoplasm
TemozolomideSmall Molecule	2	2	—	C	2 / 0	Melanoma
AmuvatinibSmall Molecule	1	1	—	D	1 / 0	Cutaneous Melanoma
DabrafenibSmall Molecule	1	—	1	B	0 / 1	Melanoma
DactolisibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
DocetaxelSmall Molecule	1	1	—	B	1 / 0	Cutaneous Melanoma
EverolimusSmall Molecule	1	1	—	D	1 / 0	Neuroblastoma
MetforminSmall Molecule	1	1	—	D	1 / 0	Malignant Neoplasm
OmipalisibSmall Molecule	1	1	—	D	1 / 0	Melanoma
RibociclibSmall Molecule	1	1	—	B	1 / 0	Cutaneous Melanoma
TanespimycinSmall Molecule	1	1	—	C	1 / 0	Melanoma
MEK Inhibitor RO4987655	1	—	1	C	—	Melanoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (47)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–47 of 47 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NRAS G13R3
Belvarafenib	Acral Lentiginous Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID13214 A patient with acral melanoma harboring NRAS G13R received belvarafenib monotherapy after four prior lines of systemic therapy and achieved stable disease as the best RECIST response. The patient rece… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC	civic
Cetuximab + IrinotecanCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	1	accepted	EID2204 One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G13R, was wildtype for KRAS, BRAF and PIK3CA… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
Panitumumab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	1	accepted	EID3842 One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G13R, was wildtype for KRAS, BRAF and PIK3CA… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
NRAS Q61K8
Belvarafenib	Acral Lentiginous Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID13218 A patient with acral melanoma harboring NRAS Q61K received belvarafenib as first-line therapy for metastatic disease after progression on adjuvant pembrolizumab and achieved stable disease as the best… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC	civic
Selumetinib	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID1475 Preclinical study in melanoma cell lines. NRAS Q61K, in addition to the BRAF V600E mutation was associated with resistance to vemurafenib but sensitivity to AZD6244 (selumetinib) in vitro in the acqui… (full text at CIViC) PMID 22194965 · Atefi et al., 2011 · Open in CIViC	civic
Vemurafenib	Cutaneous MelanomaALIAS	Predictive
NRAS Mutation14
Amuvatinib	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	1	accepted	EID1476 Preclinical study in melanoma cell lines. Cell lines (2-5/assay) with NRAS mutation were more sensitive to Amuvatinib (inhibitor targets multiple tyrosine kinases) than BRAF mutant cell lines in growt… (full text at CIViC) PMID 24950457 · Fedorenko et al., 2014 · Open in CIViC	civic
Binimetinib	Cutaneous MelanomaALIAS	Predictive	B	Supports Sensitivity Response	2	accepted	EID1472 Phase II study in 71 patients with NRAS or BRAF V600 mutant melanoma treated with MEK162. Six (20%) of 30 patients with NRAS-mutated melanoma had a partial response (three confirmed). PMID 23414587 · Ascierto et al., 2013 · Open in CIViC	civic
〃	Cutaneous MelanomaALIAS
NRAS Q615
Binimetinib	Cutaneous MelanomaALIAS	Predictive	B	Supports Sensitivity Response	2	accepted	EID1226 Phase 2 study of MEK162 in patients with advanced melanoma and NRAS or BRAF mutation. 71 patients were enrolled, 6/30 patients with NRAS mutation had a partial response (Gln61Leu 1 Patient, Gln61Lys 9… (full text at CIViC) PMID 23414587 · Ascierto et al., 2013 · Open in CIViC	civic
Selumetinib	Cutaneous MelanomaALIAS	Predictive	C	Supports Sensitivity Response	2	accepted	EID1473 Phase 1 trial in 57 patients with advanced cancers treated with selumetinib. 4 melanoma patients had NRAS Q61 mutations. One patient with NRAS mutation had 70% tumor shrinkage after three cycles of se… (full text at CIViC) PMID 18390968 · Adjei et al., 2008 · Open in CIViC	civic
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER
NRAS G12D2
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	—	accepted	EID3693 In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFO… (full text at CIViC) PMID 25666295 · Kaczirek et al., 2015 · Open in CIViC	civic
Cetuximab + IrinotecanCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID2002 One patient participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G12D and was wild type for KRAS, PIK3CA, and… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
NRAS Q179*1
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	—	accepted	EID4785 In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFO… (full text at CIViC) PMID 25666295 · Kaczirek et al., 2015 · Open in CIViC	civic
NRAS Q61R3
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	2	accepted	EID2184 Five patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61R and were wildtype for KRAS, BRAF and P… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
Belvarafenib	Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID13220 A patient with melanoma harboring NRAS Q61R received belvarafenib monotherapy after one prior line of systemic therapy and achieved stable disease as the best RECIST response. At the October 2023 data… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC	civic
Temozolomide	Melanoma	Predictive	C	Supports Sensitivity Response
NRAS G12C1
Cetuximab + ChemotherapyCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID3845 Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS G12C and were wild type for KRAS, PIK3CA, an… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
NRAS Q61L3
Cetuximab + IrinotecanCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID2181 Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61L and were wildtype for KRAS, BRAF and PI… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
Temozolomide	Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID22 In a melanoma patient with NRAS Q61L mutation, treatment with temozolomide resulted in disease free survival of 14 months. PMID 21576590 · Soon et al., 2011 · Open in CIViC	civic
Belvarafenib	Mucosal Melanoma	Predictive	C	Supports Sensitivity Response
NRAS Q61H1
Cetuximab + IrinotecanCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	2	accepted	EID3690 One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS Q61H was wildtype for KRAS, BRAF and PIK3CA.… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
BRAF V600E + HRAS Mutation + KRAS Mutation + NF1 Mutation + NRAS MutationHRAS BRAF NF1 KRAS NRAS1
Selumetinib	Malignant NeoplasmALIAS	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID11681 In this phase II study of the arm E of the NCI-COG pediatric MATCH trial, 20 patients (median age: 14) were treated with Selumetinib. High-grade glioma (n=7) and rhabdomyosarcoma (n=7) were the most c… (full text at CIViC) PMID 35363510 · Eckstein et al., 2022 · Open in CIViC	civic
BRAF V600E + HRAS Mutation + KRAS Mutation + NF1 Inactivating Mutation + NRAS MutationHRAS NF1 BRAF KRAS NRAS1
Selumetinib	Malignant NeoplasmALIAS	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID11696 In this Phase II study, 20 patients harboring activating RAS gene mutations (KRAS = 8, NRAS = 3. HRAS = 1), BRAF V600E mutations, and NF1 inactivating mutations (n=7) were treated with Selumetinib. No… (full text at CIViC) PMID 35363510 · Eckstein et al., 2022 · Open in CIViC	civic
NRAS G12A1
Belvarafenib	Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID13153 A patient with melanoma harboring NRAS G12A received belvarafenib monotherapy after two prior lines of systemic therapy and achieved a partial response as the best RECIST response. Belvarafenib treatm… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC	civic
NRAS Gain1
Binimetinib	Melanoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID6899 In melanoma preclinical models, increased NRAS expression enhanced sensitivity to binimetinib in NRAS-copy-normal A875 cells, whereas NRAS knockdown decreased binimetinib sensitivity in NRAS-gain WM26… (full text at CIViC) PMID 29245078 · Yan et al., 2018 · Open in CIViC	civic
NRAS G13D1
Tanespimycin	Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID21 Likely due to increased reliance of mutant NRAS on HSP90 for stabilization, inhibition of HSP90 by 17-AAG was shown to be effective in a patient with metastatic malignant melanoma with an NRAS G13D mu… (full text at CIViC) PMID 18375819 · Banerji et al., 2008 · Open in CIViC	civic
BRAF V600E + NRAS MutationBRAF NRAS1
Dabrafenib + VemurafenibSubstitutes	Melanoma	Predictive	B	Supports Resistance	2	accepted	EID6263 In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired r… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (333)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

openfdaRegulatory50 approval records · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Dabrafenib	US FDA	Tumor-agnostic	the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. • TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 )accelerated	approved	Mar 16, 2023	openfda
Dabrafenib	US FDA	Tumor-agnostic	the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. • TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 )accelerated	approved

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (343)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 185 recruiting · 60 active phase 3 · 1,716 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 301–343 of 343 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05919537	Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation	active not recruiting	Phase 1	68	Hummingbird BioscienceINDUSTRY	1	Apr 18, 2025	clinicaltrials
NCT06933394	Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma	recruiting	Phase 2	92	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER	1	Apr 18, 2025	clinicaltrials
NCT06925659	A Study of QLM2011 in Subjects With Advanced Solid Tumors	not yet recruiting	Phase 1	172	Qilu Pharmaceutical (Hainan) Co., Ltd.INDUSTRY	0	Apr 17, 2025	clinicaltrials
NCT05275374	XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation(ENHANCE)	not yet recruiting	Phase 1 / Phase 2	221	Xynomic Pharmaceuticals, Inc.INDUSTRY	0	Apr 10, 2025	clinicaltrials
NCT05255302	De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction(DIAL)	recruiting	Phase 2 / Phase 3	1,360	Intergroupe Francophone de Cancerologie ThoraciqueOTHER	1	Apr 1, 2025	clinicaltrials
NCT06652607	PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer(PSA-DEEP02)	recruiting	—	152	Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER	1	Mar 12, 2025	clinicaltrials
NCT03944772	Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)(ORCHARD)	active not recruiting	Phase 2	247	AstraZenecaINDUSTRY	9	Jan 30, 2025	clinicaltrials
NCT05504278	Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation	recruiting	Phase 1	144	Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY	1	Jan 27, 2025	clinicaltrials
NCT06788366	AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer	recruiting	—	2,000	IRCCS San RaffaeleOTHER	1	Jan 23, 2025	clinicaltrials
NCT06775483	Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study	not yet recruiting	Phase 2	220	Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY	0	Jan 15, 2025	clinicaltrials
NCT03709680	Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors	active not recruiting	Phase 2	128	PfizerINDUSTRY	14	Jan 14, 2025	clinicaltrials
NCT06746870	A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer	not yet recruiting	Phase 2	148	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER	0	Dec 24, 2024	clinicaltrials
NCT06739395	Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion	recruiting	Phase 2	300	Tianjin Medical University Second HospitalOTHER	1	Dec 18, 2024	clinicaltrials
NCT06718309	Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC	recruiting	Phase 2	40	First People's Hospital of HangzhouOTHER	1	Dec 5, 2024	clinicaltrials
NCT05979818	Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer(BRIO)	recruiting	Phase 1	6	Second Xiangya Hospital of Central South UniversityOTHER	1	Nov 19, 2024	clinicaltrials
NCT06411600	Combination Therapy for BRAF-V600E Metastatic CRCm(BRAVE)	recruiting	Phase 2	94	Vall d'Hebron Institute of OncologyOTHER	1	Nov 8, 2024	clinicaltrials
NCT04322890	Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation(PIKACHU)	recruiting	Phase 2	6,000	Hunan Province Tumor HospitalOTHER	1	Oct 22, 2024	clinicaltrials
NCT03635021	Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer(CR-SEQUENCE)	active not recruiting	Phase 3	419	Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER	1	Oct 21, 2024	clinicaltrials
NCT04117945	Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer	active not recruiting	Phase 2	22	Academic and Community Cancer Research UnitedOTHER	1	Sep 27, 2024	clinicaltrials
NCT06540261	The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer	active not recruiting	Phase 1	65	Ono Pharmaceutical Co., Ltd.INDUSTRY	1	Sep 19, 2024	clinicaltrials
NCT06532149	ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer(EROS)	recruiting	—	80	Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER	1	Aug 9, 2024	clinicaltrials
NCT06542731	An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer	active not recruiting	Phase 1	42	Ono Pharmaceutical Co., Ltd.INDUSTRY	1	Aug 7, 2024	clinicaltrials
NCT06537843	Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia(VenCM)	recruiting	Phase 2	100	Hospital Municipal São JoséOTHER	1	Aug 5, 2024	clinicaltrials
NCT06509126	Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer(IMPROVE-2)	recruiting	Phase 3	500	National Cancer Institute, NaplesOTHER	1	Jul 19, 2024	clinicaltrials
NCT06332170	ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors	recruiting	Phase 1	610	Hansoh BioMedical R&D CompanyINDUSTRY	1	Jul 18, 2024	clinicaltrials
NCT05159245	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs(FINPROVE)	recruiting	Phase 2	250	Helsinki University Central HospitalOTHER	1	Jul 15, 2024	clinicaltrials
NCT05462236	MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer	recruiting	Phase 2	120	AUM Biosciences Pte LtdOTHER	1	Jul 9, 2024	clinicaltrials
NCT06394713	A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors	not yet recruiting	Phase 1 / Phase 2	60	Qilu Pharmaceutical Co., Ltd.INDUSTRY	0	May 1, 2024	clinicaltrials
NCT06300177	D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure	recruiting	Phase 3	522	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY	1	Apr 26, 2024	clinicaltrials
NCT02889666	A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer(CCODG-NSCLC)	recruiting	Phase 1	500	Shanghai Jiao Tong University School of MedicineOTHER	1	Apr 17, 2024	clinicaltrials
NCT03494946	Liver Transplantation Compared to Chemotherapy in Patients With ColoRectal Cancer(SECAIII)	recruiting	N/A	30	Oslo University HospitalOTHER	1	Feb 6, 2024	clinicaltrials
NCT02925234	The Drug Rediscovery Protocol (DRUP Trial)(DRUP)	recruiting	Phase 2	1,550	The Netherlands Cancer InstituteOTHER	1	Jan 24, 2024	clinicaltrials
NCT06121700	Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer(Miracle-G)	recruiting	Phase 2	55	Fudan UniversityOTHER	1	Nov 8, 2023	clinicaltrials
NCT06102837	Tumor Vaccines for Solid Tumors	recruiting	—	340	Huashan HospitalOTHER	1	Oct 26, 2023	clinicaltrials
NCT05777278	Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression	recruiting	Phase 1 / Phase 2	29	The First Affiliated Hospital of Guangzhou Medical UniversityOTHER	1	Oct 10, 2023	clinicaltrials
NCT06067776	Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer	not yet recruiting	Phase 1	36	Jonathan RiessOTHER	1	Oct 5, 2023	clinicaltrials
NCT04728724	Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer	recruiting	Phase 2	100	Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER	1	Sep 13, 2023	clinicaltrials
NCT03563729	Melanoma Metastasized to the Brain and Steroids(MEMBRAINS)	recruiting	Phase 2	80	Inge Marie SvaneOTHER	1	Jul 13, 2023	clinicaltrials
NCT05725200	Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer(EVIDENT)	recruiting	Phase 2	40	Oslo University HospitalOTHER	1	Feb 21, 2023	clinicaltrials
NCT05429515	Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury	not yet recruiting	Phase 4	50	Peking Union Medical College HospitalOTHER	0	Jun 23, 2022	clinicaltrials
NCT05186506	A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer	not yet recruiting	Phase 2	152	Sichuan UniversityOTHER	0	Jan 11, 2022	clinicaltrials
NCT01638676	A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients	recruiting	Phase 1 / Phase 2	55	University of LouisvilleOTHER	1	Oct 29, 2021	clinicaltrials
NCT04045691	Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment(BERING)	recruiting	—	750	Pierre Fabre Pharma GmbHINDUSTRY	3	Jan 19, 2021	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (13)

Drugs with predictive evidence (20)

Predictive evidence items (47)

Approvals mentioning the linked drugs (333)

Active trials (343)

Linked publications (37)